Geelong, Australia (31st October, 2008). Verva Pharmaceuticals Ltd.
announced today that CEO Vince Wacher will be an invited panelist in the "Partnering and Licensing" panel discussion at the GTCbio 4th Annual Metabolic Diseases World Summit. The panel will be moderated by Mike McCully, Senior Manager at Deloitte Recap LLC. Other confirmed panelists are Dr. Robert Knowles, Senior Director, Worldwide Business Development, Pfizer, Inc. and Dr. David Glass, Director, Technology Transfer, Joslin Diabetes Center. The panel discussion will take place at 5:00 pm US EST on Thursday 6th November, 2008 at Le Meridien Hotel in Cambridge, Massachusetts. Conference details can be found at www.gtcbio.com.
Verva Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company developing novel therapies to treat diabetes and to prevent and treat obesity. Verva's lead product VVP808 is a non-thiazolidinedione insulin sensitizer entering phase 1b/2a clinical safety and efficacy testing in type
2 diabetes. VVP808 was previously approved in North America in an unrelated indication; its unexpected anti-diabetic activity was identified by Verva using the MRU-developed GES platform. Verva's pipeline includes: (i) an accelerated discovery program developing next-generation diabetes therapies based on VVP808 structure and mode-of-action; (ii) expansion of the GES platform to discover new types of optimized diabetes therapies; and (iii) preclinical proof-of-concept with two obesity-focused technologies that block de novo fat formation. Further information can be found on the company's website www.vervapharma.com.